TTI-101, also known as C188-9, is a small molecule inhibitor that specifically targets the STAT3 pathway. STAT3 is a transcription factor that plays a critical role in cell growth and survival. Dysregulation of STAT3 signaling is implicated in various cancers, making it a promising target for cancer therapy.
